

Acknowledgement to Referees

© Springer Nature Switzerland AG 2022

Dear Reader,

Welcome to the final issue of *Targeted Oncology* for 2022.

I wish to reflect on this year's achievements, and to thank all those who have contributed their time and effort to guarantee the quality of the content published in the journal.

In 2022, more than 60 articles have been published. The most popular of these in terms of downloads from SpringerLink have been:

[Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features](#)

[Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study](#)

[Molecular Pathogenesis of Sporadic Desmoid Tumours and Its Implications for Novel Therapies: A Systematised Narrative Review](#)

[Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System](#)

[Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis](#)

[A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China](#)

[Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma](#)

[The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours](#)

[Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP](#)

[Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice](#)

The high quality of content published in *Targeted Oncology* has been reflected in the most recent impact factor of 4.864 and CiteScore™ of 7.2. Further, *Targeted Oncology* has published content in a timely manner, with an average time from submission to first decision of just 6 days.

The COVID-19 pandemic has continued to present many challenges and I would like to thank all who have contributed to ensuring the journal has thrived despite the ongoing issues.

I would like to start by thanking the authors of the articles published in *Targeted Oncology* over the course of 2022. The enthusiasm of all authors for their chosen fields and their willingness to contribute content to the journal are crucial for its continued success.

The quality of published articles is also testament to the diligence of the peer reviewers. I would like to acknowledge the following individuals who acted as reviewers for *Targeted Oncology* in the last 12 months:

Omar Alhalabi, USA
Kazuhiro Araki, Japan
Edouard Auclin, France
Christina Baik, USA
David Bajor, USA
Sandro Barni, Italy
Todd Bauer, USA

Robert A. Beckman, USA
 Christiana Bellan, Italy
 Burkhard Brandt, Germany
 Andreas Bruchbacher, Austria
 Alan Bryce, USA
 Minghui Cao, USA
 David Cella, USA
 Joanne Chiu, Hong Kong, China
 Bartosz Chmielowski, USA
 Shih-Feng Cho, Taiwan, Republic of China
 Christos Chouaid, France
 Petros Christopoulos, Germany
 Lisa Cordes, USA
 Gina D'Amato, USA
 Nancy Davis, USA
 Theo M. de Reijke, the Netherlands
 Deborah Doroshov, USA
 Eva Ellebaek, Denmark
 Carles Escriu, UK
 Camille Evrard, France
 Martin Faehling, Germany
 Cindy Franklin, Germany
 Corinne Frere, France
 Patrizia Froesch, Switzerland
 Nobukazu Fujimoto, Japan
 Carolina Gabay, Argentina
 Juan Esteban Garcia-Robledo, USA
 John Gordan, USA
 Christian Grohe, Germany
 Paul Hergenrother, USA
 Michael Heskett, USA
 Cinta Hierro, Spain
 Sarah A. Holstein, USA
 Susan Hsiao, USA
 Ping-Chih Hsu, Taiwan, Republic of China
 Wade Iams, USA
 Oliver Illini, Austria
 Alice Indini, Italy
 Albert Jang, USA
 William Kelly, USA
 Ali Raza Khaki, USA
 Yoshinobu Koguchi, USA
 Jakub Kucharz, Poland
 Kei Kunimasa, Japan
 Annika Kurreck, Germany
 Yok-Lam Kwong, Hong Kong, China
 Theodore W. Laetsch, USA
 David Lang, Austria
 Igor Latorzeff, France
 Peter Kar Han Lau, Australia
 Christophe Le Tourneau, France
 Joycelyn Lee, Singapore
 Yong Li, China
 Wan-Teck Lim, Singapore
 Chia-Chi Lin, Taiwan, Republic of China
 Margaret Macy, USA
 Ashish Manne, USA
 Tomer M. Mark, USA
 Francesco Massari, Italy
 Stefano Mastrangelo, Italy
 Bradley A. McGregor, USA
 Xabier Mielgo-Rubio, Spain
 Satoru Miura, Japan
 Tomohiro Mizuno, Japan
 Florian Moik, Austria
 Alessandro Morabito, Italy
 Aki Morikawa, USA
 Christopher Nevala-Plagemann, USA
 Jorge Nieva, USA
 Inger Nijhof, the Netherlands
 Ajay K. Nooka, USA
 Yusuke Okuma, Japan
 Marc Oliva, Spain
 Hiroki Osumi, Japan
 Sai-Hong I. Ou, USA
 Mehmet Fevzi Ozkaynak, USA
 Aliyah Pabani, Canada
 Emmanouil Panagiotou, Greece
 Francesco Passiglia, Italy
 Jai N. Patel, USA
 Tejas Patil, USA
 Anne Patsouris, France
 Edward Pickering, USA
 Adam Plużański, Poland
 Amy Prawira, Australia
 Jo Raskin, Belgium
 Elie Rassy, France
 Nityam Rathi, USA
 Olivier Rixe, USA
 Tadeusz Robak, Poland
 Pedro Rodrigues, Spain
 Daniele Rossini, Italy
 Antonio Russo, Italy
 Saeed Sadeghi, USA
 Wolfram Samlowski, USA
 Scott M. Schuetze, USA
 John F. Seymour, Australia
 Tatsunori Shimoi, Japan
 Martin Simkovic, Czech Republic
 Rory Smoot, USA
 Pierre P.J. Souquet, France
 Haruhiko Sugimura, Japan
 Adam Szpechcinski, Poland
 Motoko Tachihara, Japan
 Hideki Takeshita, Japan
 Aaron C. Tan, Singapore

Junko Tanizaki, Japan
 Benjamin Teply, USA
 Rob ter Heine, the Netherlands
 Toshiki Terao, Japan
 Shanmugapriya Thangavadiel, USA
 Toby Trahair, Australia
 Hibiki Udagawa, Japan
 Manuel Valladares-Ayerbes, Spain
 Greet Van De Sijpe, Belgium
 Paul Viscuse, USA
 Panagiotis Vlachostergios, USA
 Srinivas Vourganti, USA
 Yufeng Wang, USA
 Florian Wegwitz, Germany
 Howard West, USA
 Kakuhiro Yamaguchi, Japan
 Toshinari Yamashita, Japan
 Takafumi Yanagisawa, Austria
 Rinat Yerushalmi, Israel
 Kan Yoenmori, Japan
 Kazuhiro Yoshimura, Japan
 Marjorie G. Zauderer, USA
 Yoshitaka Zenke, Japan
 Yujie Zhao, USA

I also very grateful to the members of the journal's Honorary Editorial Board, who have acted as peer reviewers and authors, and have provided guidance on journal content, policy, and processes:

James Armitage, University of Nebraska Medical Center, Omaha, NE, USA
 James Berenson, Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, USA
 Jean-Yves Blay, University Claude Bernard Lyon I, Lyon, France
 Tomas Buchler, Charles University and Thomayer Hospital, Prague, Czech Republic
 Ann-Lii Cheng, National Taiwan University, Taipei, Taiwan, Republic of China
 Chao-Hua Chiu, Taipei Medical University Hospital, Taipei, Taiwan
 Fortunato Ciardiello, Second University of Naples, Naples, Italy
 Jayesh Desai, The Royal Melbourne Hospital, Melbourne, VIC, Australia
 Sandrine Faivre, Beaujon University Hospital, Clichy, France
 Giuseppe Giaccone, Weill Cornell Medicine, New York, NY, USA
 Petros Grivas, University of Washington, Seattle, WA, USA

Balazs Halmos, Montefiore Medical Center, New York, NY, USA
 Gabriel Hortobagyi, Houston, TX, USA
 Christian Jackisch, Sana Klinikum, Offenbach, Germany
 V. Craig Jordan, MD Anderson, Houston, Texas, USA
 John Kirkwood, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
 Heinz-Josef Lenz, University of Southern California, Los Angeles, CA, USA
 Teresa Macarulla, Vall d'Hebron University Hospital, Barcelona, Spain
 Mark McKeage, University of Auckland, Auckland, New Zealand
 Alain Mita, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA
 Monica Mita, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA
 Jean-François Morère, Hôpital Avicenne, Paris-Nord, France
 Athanasios Papavassiliou, National and Kapodistrian University of Athens, Athens, Greece
 Camilo Porta, IRCCS San Matteo University Hospital Foundation, Pavia, Italy
 Timothy Price, The Queen Elizabeth Hospital, Adelaide, SA, Australia
 Shukui Qin, Chinese Society of Clinical Oncology, Nanjing, China
 Eric Raymond, Groupe Hospitalier Paris Saint-Joseph, Paris, France
 Richard Riedel, Duke University, Durham, NC, USA
 Helen Rizos, Macquarie University, North Ryde, NSW, Australia
 Hironga Satake, Kochi Medical School, Nankoku, Japan
 Nicole Shonka, University of Nebraska Medical Center, Omaha, NE, USA
 Denis Soulières, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada
 Yu Sunakawa, St. Marianna University School of Medicine, Kawasaki, Japan
 Eric Van Cutsem, University Hospitals Leuven, Leuven, Belgium
 Tian Zhang, UT Southwestern Medical Center, Dallas, TX, USA
 David Ziegler, Sydney Children's Hospital, Randwick, NSW, Australia

I am pleased to let you know that the Adis journal portfolio has a new member. [Molecular and Cellular Pediatrics](#) is a PubMed- and Scopus-indexed, open access journal publishing peer-reviewed articles on innovative research in pediatrics. The journal is dedicated to the exchange and discussion of current molecular and cellular concepts in pediatrics. This

includes frontline reviews on the latest developments, original research articles, and a forum for discussion of pathophysiological concepts including therapeutic approaches. *Molecular and Cellular Pediatrics* is an official journal of the German Society of Child and Adolescent Medicine (Deutsche Gesellschaft für Kinder- und Jugendmedizin e.V., DGKJ).

Returning to *Targeted Oncology*, the editorial program for 2023 is well under way, and I am looking forward to bringing you many high-quality and authoritative articles in the field of *Targeted Oncology* over the coming year.

I thank you for your continued support.

With best wishes,
Martin Chopra